OPN-375
Drug
OptiNose US, Inc.
Total Payments
$3.5M
Transactions
494
Doctors
3
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $2.0M | 275 | 0 |
| 2019 | $1.4M | 209 | 3 |
| 2018 | $57,319 | 10 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 494 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | Optinose US, Inc. | $1.7M | 0 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | Optinose US, Inc. | $988,133 | 0 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | Optinose US, Inc. | $237,483 | 0 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | Optinose US, Inc. | $227,658 | 0 |
| A 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 g Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. OPN-FLU-NP-3103 | Optinose US, Inc. | $148,636 | 0 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | Optinose US, Inc. | $93,836 | 0 |
| A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adults with Bilateral Nasal Polyps using Nasoendoscopic Video OPN-FLU-NP-3104 | Optinose US, Inc. | $49,350 | 0 |
| A 24-Week Open-Label Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adults with Bilateral Nasal Polyps using Nasoendoscopic Video OPN-FLU-NP-3104 | OptiNose US, Inc. | $46,069 | 0 |
| A 24-Week Randomized,Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal administration of 186 and 372 microgram of OPN-375 BID in Subjects with CS with or without the presence of Nasal Polyps ONP-FLU-CS-3205 | OptiNose US, Inc. | $14,323 | 0 |
| A 16-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 micrograms Twice a Day BID in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase OPN-FLU-NP-3103 | OptiNose US, Inc. | $11,250 | 0 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205. | OptiNose US, Inc. | $6,374 | 2 |
| A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day BID in Subjects with Chronic Sinusitis Without the Presence of Nasal Polyps. OPN-FLU-CS-3206. | OptiNose US, Inc. | $2,291 | 1 |
Ad
Manufacturing Companies
- Optinose US, Inc. $3.4M
- OptiNose US, Inc. $80,307
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 3
- Transactions 494
About OPN-375
OPN-375 is a drug associated with $3.5M in payments to 3 healthcare providers, recorded across 494 transactions in the CMS Open Payments database. The primary manufacturer is OptiNose US, Inc..
Payment data is available from 2018 to 2020. In 2020, $2.0M was paid across 275 transactions to 0 doctors.
The most common payment nature for OPN-375 is "Unspecified" ($3.5M, 100.0% of total).
OPN-375 is associated with 12 research studies, including "A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 g of OPN-375 Twice a Day (BID) in Subjects with Chronic Sinusitis With or Without the Presence of Nasal Polyps. OPN-FLU-CS-3205." ($1.7M).